Successful clinical trial in COVID with Heparin in Pulmospray
Clinical trial success in COVID19 with heparin in Pulmospray®.
Istanbul University, Professor Dr. Mustafa Erelel and Professor Dr. Ayca Yildiz-Pekoz, recently completed their investigator-supported clinical study with low molecular weight heparin with our Pulmospray device. Resyca donated these devices to this COVID-related research program at the start of the pandemic.
Investigators reported promising results of the study that included 80 patients, whereof 40 patients inhaled heparin with the Pulmospray®.
Clinical trial results suggest that low molecular weight heparin inhalation with Pulmospray® may be a treatment option to reduce intensive care and improve clinical status. Positive results also indicate that the Pulmospray inhaler was applied effectively by clinical trial staff and users in a single use, single patient application in the infectious disease COVID-19.
The publication of study results was submitted for publication and is currently in review.
The results have already been published at clinical trials dot gov.
